Compare HEI & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HEI | NTRA |
|---|---|---|
| Founded | 1957 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.8B | 45.3B |
| IPO Year | 1995 | 2015 |
| Metric | HEI | NTRA |
|---|---|---|
| Price | $352.34 | $328.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 15 |
| Target Price | ★ $357.08 | $259.07 |
| AVG Volume (30 Days) | 392.7K | ★ 1.4M |
| Earning Date | 05-26-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.09% | N/A |
| EPS Growth | ★ 33.51 | 0.65 |
| EPS | ★ 3.01 | N/A |
| Revenue | ★ $4,485,044,000.00 | $210,939,000.00 |
| Revenue This Year | $14.27 | $18.08 |
| Revenue Next Year | $8.60 | $19.65 |
| P/E Ratio | $117.95 | ★ N/A |
| Revenue Growth | ★ 16.26 | N/A |
| 52 Week Low | $256.11 | $157.43 |
| 52 Week High | $376.86 | $333.56 |
| Indicator | HEI | NTRA |
|---|---|---|
| Relative Strength Index (RSI) | 45.16 | 68.06 |
| Support Level | $331.21 | $187.64 |
| Resistance Level | $356.13 | N/A |
| Average True Range (ATR) | 8.20 | 10.93 |
| MACD | -2.63 | 1.95 |
| Stochastic Oscillator | 8.63 | 90.53 |
Heico is an aerospace and defense supplier that focuses on creating replacement parts for commercial aircraft and components for defense products. In commercial aerospace, Heico is the largest independent producer of replacement aircraft parts. In the defense market, the company produces niche subcomponents used in targeting technology as well as simulation equipment, among other categories. It operates two segments: the flight support group and the electronic technologies group. Both supply the aerospace and defense sectors to different degrees. Heico is persistently acquisitive, focusing on companies in similar or adjacent markets that offer strong cash flow and profitable growth potential.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.